News

The company is focused on developing targeted and programmable therapeutics called Accurins. Both the firms have notified each other that they will not be exercising their options to

Currently, andexanet alfa is in Phase III ANNEXA (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. The antidote is designed to reverse the

The patent relates to Collegium’s Oxycodone DETERx formulation and contains claims that cover the Company’s lead product, an abuse-deterrent, extended-release oxycodone product utilizing its proprietary DETERx technology. Collegium

Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. Defibrotide is a novel product

Testosterone Gel (1%) offers once-daily dosing, 24-hour coverage and three configurations: unit-dose tubes and packets and metered-dose pumps. Vogelxo and Testosterone Gel are a prescription medicine that contains

The patent will be in effect at least until May 2031. This patent covers the technology used in Eye-D®, the company’s controlled-release latanoprost insert currently in a Phase

ELELYSO is the first prescription medication to be certified kosher by the OU, a milestone for the brand which was approved by the U.S. Food and Drug Administration

The MAAs are based on data from the large Phase III TOviTO clinical trial program and further regulatory filings in other countries will be announced in due course.

The company has submitted national marketing authorization variations for Somatuline Autogel 120mg injection to the drug regulatory authorities in 25 countries of the EU. Upon submissions in EU